The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Roger Barker is the Professor of Clinical Neuroscience at the University of Cambridge and a Consultant Neurologist at the Addenbrooke’s Hospital Cambridge. He is a PI in the MRC-Wellcome Stem Cell Institute in Cambridge and Director of the MRC funded UKRMP Stem and Engineered cell hub.
Professor Barker’s research seeks to better define the clinical heterogeneity of two common neurodegenerative disorders of the CNS- namely Parkinson’s and Huntington’s disease. This has helped him define the best way to take new therapies into the clinic including novel experimental therapeutics.
Lund University, Lund, Sweden
Gesine Paul-Visse is a consultant neurologist and professor of Neurology at Lund University (LU) and Skåne University Hospital, Sweden. She trained at the Charité in Berlin, UMDS in London and St Andrews University, Scotland. Attracted by Lund as a worldwide pioneering center for neurotransplantation, she joined the lab of Prof. Patrik Brundin supported by an EU Marie Curie postdoc fellowship. Since 2011, she leads a preclinical research group “Translational Neurology” at LU with a focus to understand mechanisms of neurodegenerative disorders, in particular how neurovascular changes contribute to neurodegeneration.
Bridging the lab and the clinic, Gesine Paul-Visse is a clinical research fellow in at the Wallenberg Center for Molecular Medicine and also investigator in several clinical trials addressing the neurorestorative effect of growth factors and cell transplantation in Parkinson’s disease. Her vision is to contribute to the development of therapies not only leading to therapeutic improvement but structural regeneration.
Lund University, Lund, Sweden
Malin Parmar is a professor in cellular neuroscience at Lund University in Sweden and a New York Stem Cell Foundation – Robertson investigator. Together with her lab she has shown in a series of high-profile publications how human fibroblasts can be converted into neurons, how glial cells can be reprogrammed into neurons in vivo, and how functional dopamine neurons can be generated from human embryonic stem cells.
Professor Parmar is the recipient of an ERC starting grant and an ERC Consolidator grant. Her research has a strong translational focus, she leads the European effort STEM-PD, designed to bring stem cell-derived dopamine neurons to clinical trials, and she collaborates within European and International networks as well as Industry partners to develop new, cell-based therapies for Brain Repair with focus on Parkinson’s Disease.